121 - Treatment and Management of COVID-19: An Update

Friday, October 21, 2022

10:30 AM – 11:45 AM US ET

Location: 146 ABC

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Adarsh Bhimraj, MD

Director, Infectious Diseases Fellowship and Education
Division of Infectious Diseases, Houston Methodist Hospital
Houston Methodist Hospital
Houston, TX, United States

Disclosure(s): No financial relationships to disclose
Natasha Chida, MD, MSPH

Assistant Professor
Johns Hopkins School of Medicine
Baltimore, MD, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Ethel Weld, MD, PhD

Assistant Professor of Medicine
Johns Hopkins
Baltimore, MD, United States

Disclosure(s): No financial relationships to disclose

Slides
Rajesh Gandhi, MD

Professor of Medicine
Harvard Medical School
Boston, MA, United States

Disclosure(s): No financial relationships to disclose

Slides
Eduardo López Medina, MD, MSc

Scientific Director
Centro de Estudios en Infectología Pediátrica, CEIP
Cali, Valle del Cauca, Colombia

Disclosure(s): AstraZenca: Grant/Research Support (Ongoing); GlaxoSmithKline (GSK): Grant/Research Support (Ongoing); Janssen Pharmaceutical Company of J&J: Grant/Research Support (Ongoing); Merck Sharp & Dohme (MSD): Grant/Research Support (Ongoing); Sanofi Pasteur Inc.: Grant/Research Support (Ongoing); Takeda Vaccines: Grant/Research Support (Ongoing)

Slides

Disclosure(s):

Adarsh Bhimraj, MD: No financial relationships to disclose

Natasha Chida, MD, MSPH: No financial relationships to disclose

Ethel D. Weld, MD, PhD: No financial relationships to disclose

Rajesh Gandhi, MD: No financial relationships to disclose

Eduardo López Medina, MD, MSc: AstraZenca: Grant/Research Support (Ongoing); GlaxoSmithKline (GSK): Grant/Research Support (Ongoing); Janssen Pharmaceutical Company of J&J: Grant/Research Support (Ongoing); Merck Sharp & Dohme (MSD): Grant/Research Support (Ongoing); Sanofi Pasteur Inc.: Grant/Research Support (Ongoing); Takeda Vaccines: Grant/Research Support (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the clinical approach to adult and pediatric patients when considering pharmacologic treatments for COVID-19;
describe the therapeutic agents available to treat mild to moderate COVID-19 and describe the rationale for their use;
outline the therapeutic agents available to treat severe and critical COVID-19 and describe the rationale for their use

Presentations:

10:30 AM – 10:55 AM US ET

Update on Treatment of Mild & Moderate COVID-19
Speaker: Ethel D. Weld, MD, PhD – Johns Hopkins
10:55 AM – 11:20 AM US ET

Update on Treatment of Severe & Critical COVID-19
Speaker: Rajesh Gandhi, MD – Harvard Medical School
11:20 AM – 11:45 AM US ET

Pediatric Considerations for the Treatment of COVID-19
Speaker: Eduardo López Medina, MD, MSc – Centro de Estudios en Infectología Pediátrica, CEIP